GT Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	8.92	6.81	3.95	1.08	5.67	8.97
Short-Term Investments	-	-	-	12.89	10.84	23.01
Cash & Short-Term Investments	8.92	6.81	3.95	13.97	16.51	31.98
Cash Growth	277.29%	72.39%	-71.72%	-15.36%	-48.38%	503.72%
Other Current Assets	0.66	0.73	0.09	0.08	0.05	0.19
Total Current Assets	9.59	7.54	4.04	14.06	16.56	32.17
Net Property, Plant & Equipment	-	-	-	0.05	0.17	-
Other Long-Term Assets	-	-	-	-	0.01	-
Total Assets	10	8.11	4.23	14.11	16.74	32.17
Accounts Payable	0.25	0.75	3.85	4.33	3.14	8.19
Accrued Expenses	2.16	1.56	1.8	1.2	1.67	1.9
Short-Term Debt	-	-	-	-	-	0.03
Current Portion of Leases	-	-	-	0.06	0.11	-
Other Current Liabilities	-	-	-	1.05	0.02	0.14
Total Current Liabilities	2.42	2.32	5.9	6.63	4.94	10.26
Long-Term Leases	-	-	-	-	0.06	-
Total Long-Term Liabilities	-	-	-	-	0.06	-
Total Liabilities	2.42	2.32	5.9	6.63	5	10.26
Preferred Stock	0	0	-	0	0	0
Common Stock	0.04	0.03	0	0	0.03	1.15
Additional Paid-in Capital	734.38	729.66	693.55	689.54	686.17	674.35
Retained Earnings	-726.84	-723.9	-695.23	-682.07	-674.47	-653.58
Shareholders' Equity	7.58	5.79	-1.67	7.48	11.73	21.91
Total Liabilities & Equity	10	8.11	4.23	14.11	16.74	32.17
Total Debt	-	0	0	0.06	0.17	0.03
Net Cash (Debt)	8.92	6.81	3.95	13.91	16.33	31.95
Net Cash Growth	31.01%	72.39%	-71.60%	-14.82%	-48.87%	-
Net Cash Per Share	0.71	1.24	2.08	10.32	15.38	34.04
Book Value	7.58	5.79	-1.67	7.48	11.73	21.91
Book Value Per Share	0.61	1.05	-0.88	5.55	11.05	23.35
Tangible Book Value	7.58	5.79	-1.67	7.48	11.73	21.91
Tangible Book Value Per Share	0.61	1.05	-0.88	5.55	11.05	23.35

SEC Filings: 10-K · 10-Q